Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Loxo,Bayer gets U.S...

    Loxo,Bayer gets U.S approval for cancer drug Larotrectinib

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-28T09:06:43+05:30  |  Updated On 17 Aug 2021 12:00 PM IST

    New Delhi: A Loxo Oncology Inc drug larotrectinib shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.


    The drug, larotrectinib, will be sold under the brand name Vitrakvi and priced at $32,800 per month, in partnership with Bayer AG. It will be Loxo's first commercial medicine.


    Kevin O'Leary, Bayer's vice president of pricing and contracting, said Bayer and Loxo will assist patients financially and offer a value-based program, refunding both out-of-pocket and insurer payments for patients who do not see a clinical benefit within the first three months of treatment.


    The mutation, known as TRK fusion, occurs in no more than 3,000 Americans each year, or less than 1 per cent of patients with solid tumour cancers, according to Bayer.


    The FDA said it approved Vitrakvi for adults and pediatric patients who have advanced solid tumour cancers with the gene mutation that has progressed after other treatments.


    In a 122-patient clinical trial, larotrectinib significantly reduced tumours in 81 per cent of those with 24 different types of cancer, including lung, pancreatic, breast, thyroid, colon and soft tissue sarcomas. Researchers reported an extremely mild side effect profile for the medicine.


    "Today's approval marks another step in an important shift toward treating cancers based on their tumour genetics rather than their site of origin in the body," FDA Commissioner Scott Gottlieb said in a statement.


    Merck & Co's Keytruda last year became the first cancer drug to win approval for a so-called tumour-agnostic use, though that remains a small market for the big-selling drug.


    Currently, most cancer patients are not routinely tested for tumour mutations, making it difficult to find those who will benefit from the drug. O'Leary said in a phone interview that Bayer is talking with payers about expanding testing.


    Oppenheimer has forecast annual larotrectinib sales of more than $1 billion by 2024.


    Loxo is also developing a drug, LOXO-292, that targets another rare gene fusion mutation known as RET, seen in thyroid, lung and other cancers. Loxo and Bayer have a follow-up TRK drug in development known as LOXO-195.


    Similar drugs being developed by Roche and others are expected to fuel increased demand for advanced genetic testing of tumours in order to identify the patients likely to benefit from the treatments.


    The U.S. government earlier this year said the Medicare program for Americans aged 65 and older will cover so-called next-generation sequencing, which looks for hundreds of mutations across all solid tumours, for advanced cancer patients.


    Also Read: Loxo-Bayer cancer drug gets priority review from FDA
    approvalBayercancerdruglarotrectinibLoxomedicinemutationOppenheimerUSFDAvitrakvi
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok